Impax Laboratories Receives Tentative FDA Approval For Generic FLOMAX(R) 0.4mg CapsulesMain Category: Urology / NephrologyAlso Included In: Regulatory Affairs / Drug Approvals Article Date: 07 Oct 2009 Impax Laboratories, Inc. (NASDAQ: IPXL) confirmed that the U.S. Food and Drug Administration (FDA) has granted tentative approval of the Company's Abbreviated New Drug Application (ANDA) for generic version of FLOMAX® (tamsulosin hydrochloride) 0.4mg capsules. Boehringer Ingelheim Pharmaceuticals, Inc. markets FLOMAX® for the functional symptoms of benign prostatic hyperplasia. According to Wolters Kluwer Health, U.S. sales of Flomax® 0.4mg capsules were approximately $1.9 billion for the 12 months ended August 31, 2009. Source Impax Laboratories, Inc. Original article posted on Medical News Today. Articles not to be reproduced without permission of Medical News Today Medical News Today publishes the latest health news and health videos for consumers and health professionals. It has a searchable archive of over 100,000 health news articles. < back to medical news
|
||||
|





